Is HIMS Stock Ready For A Rebound After A 60% Fall?
Hims & Hers Health (NYSE: HIMS), a telehealth platform, has seen a steep decline recently, with its stock plunging 60% from February highs of over $70 to below $30. Long-term investors may find this familiar—HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it dropped 77%.
Amid shortages of weight loss drugs from Eli Lilly and Novo Nordisk, HIMS benefited by offering compounded versions. Now that supply constraints have eased, HIMS has transitioned to offering branded medications through its telehealth services, including Eli Lilly's in-demand Zepbound. For those seeking upside with lower volatility than individual stocks, take a look at the High-Quality portfolio, which has beaten the S&P 500 with returns exceeding 91% since its inception.
Several growth indicators look promising. Total subscribers on the Hims & Hers platform have soared from 0.5 million in 2021 to 2.2 million today. Additionally, average revenue per subscriber has risen from $51 to $64 during the same period. With expanding offerings driving subscriber growth, the company expects 2025 sales to grow 58% to $2.35 billion. Despite recent market turbulence, analysts still peg the average price target at $45—implying a potential 50% upside from current levels.
Markets can remain volatile, and fear often clouds judgment. However, for long-term investors, HIMS' strong financials and growth outlook may reward patience. For those seeking reduced risk, a more balanced investment approach like the Trefis Reinforced Value Portfolio, which has outperformed its all-cap benchmark, could offer more stability while still tapping into potential gains. Why is that? This portfolio's quarterly rebalancing of large-, mid-, and small-cap stocks enables it to capture gains during rallies while cushioning downside risks, as outlined in the RV Portfolio performance metrics.
Invest with Trefis
Market Beating Portfolios | Rules-Based Wealth
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Bausch Health (BHC) Climbs 45% on Insider Buying
We recently published . Bausch Health Companies Inc. (NYSE:BHC) is one of the last week's top performers. Bausch Health jumped by 45.04 percent week-on-week, on a combination of bargain-hunting and mirroring an insider purchase last Friday. In a regulatory filing, Bausch Health Companies Inc. (NYSE:BHC) said that Paulson Capital Inc. and its affiliates acquired 34.7 million of its shares from Carl C. Icahn and affiliates, effectively boosting its total ownership to 19.13 percent. Following the transaction that saw the sellers' shares fall below the threshold to earn a board seat, the Icahn Group officially exited Bausch Health Companies Inc.'s (NYSE:BHC) higher management. Copyright: nimon / 123RF Stock Photo Additionally, Brett M. Icahn and Steven D. Miller have resigned from the company's board of directors. In recent news, Bausch Health Companies Inc. (NYSE:BHC) expanded its attributable net income by 1,380 percent in the second quarter of the year to $148 million from only $10 million in the same period last year. Revenues also grew by 5 percent to $2.53 billion from $2.4 billion. While we acknowledge the potential of BHC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Sign in to access your portfolio
Yahoo
21 minutes ago
- Yahoo
Why IBM's High Valuation Has Analysts Concerned
International Business Machines Corporation (NYSE:) is one of the On August 14, Erste Group analyst Hans Engel downgraded the stock from Buy to Hold, reflecting the challenges IBM is facing in accelerating its revenue growth to contest broader technology sector performance. According to the analysts, IBM's sales growth is 'well below' the sector average which isn't expected to change this year. They believe that current valuation is 'high in view of the below-average growth prospects.' 'IBM's sales growth is well below the sector average. This is not expected to change this year either. The Group's latest forecast for 2025 assumes moderate revenue growth of at least +5% (y/y). The free cash flow forecast has been left at USD 13.5 bn. The current P/E ratio of the stock is high in view of the below-average growth prospects.' JuliusKielaitis / International Business Machines Corporation (NYSE:IBM) is a multinational technology company and a pioneer in artificial intelligence, offering AI consulting services and a suite of AI software products. While we acknowledge the potential of IBM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Eli Lilly Taps High-Grade Market With Rare 40-Year Paper
(Bloomberg) -- Eli Lilly & Co. is tapping the US investment-grade debt market with a deal that's expected to include a 40-year bond, a rarity in a market characterized by high borrowing costs. The drugmaker is selling debt in as many as seven parts, with 40-year tranche set to yield 0.73 percentage point above Treasuries, according to a person familiar with the matter. Initial price discussions called for a yield in the area of 1.05 percentage points above the benchmark. A Photographer's Pipe Dream: Capturing New York's Vast Water System Festivals and Parades Are Canceled Amid US Immigration Anxiety A London Apartment Tower With Echoes of Victorian Rail and Ancient Rome Princeton Plans New Budget Cuts as Pressure From Trump Builds The deal is also expected to include a 30-year portion, as well as maturities ranging from 3 years to 10 years, the person said, asking not to be identified discussing private information. The offering comes amid a dearth of supply of long-dated corporate bonds: Just 11% of high-grade debt sold this year had a maturity of 30 years or more, down from 15% in 2024, as companies have been reticent to lock in elevated borrowing costs for long periods of time. Eli Lilly is one of nine companies selling US high-grade debt on Monday, with McDonald's Corp., Marriott International Inc. and Charter Communications Inc. among the others. Borrowers are piling in ahead of a seasonal slowdown later this month. They're also taking advantage of more favorable funding conditions: Yields this month are sitting consistently below 5% for the first time this year, yet demand continues to be robust. Most recently, investment-grade order books grew to more than five times the size of fresh supply on Wednesday, while borrowers paid just two basis points in new-issue concessions — both better than average so far this year. Citigroup Inc., Goldman Sachs Group Inc., JPMorgan Chase & Co., Mizuho Financial Group Inc. and Morgan Stanley are managing Eli Lilly's sale, with proceeds earmarked for general corporate purposes. The bonds are expected to be rated Aa3 by Moody's Ratings and A+ by S&P Global Ratings. Issuer Profile Debt distribution: LLY US Equity DDIS Capital structure: LLY US Equity CAST Related securities: LLY US Equity RELS Ratings history: LLY US Equity CRPR --With assistance from Michael Gambale and Boris Korby. (Updates with guidance numbers in second paragraph.) Foreigners Are Buying US Homes Again While Americans Get Sidelined What Declining Cardboard Box Sales Tell Us About the US Economy Americans Are Getting Priced Out of Homeownership at Record Rates Living With 12 Strangers to Ease a Housing Crunch Bessent on Tariffs, Deficits and Embracing Trump's Economic Plan ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
